JWH-161
This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 20:45, 20 September 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Dr). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Identifiers | |
---|---|
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H33NO2 |
Molar mass | 403.555 g/mol g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB1 receptor. While retaining structural elements from both families, JWH-161 has a CB1 Ki of 19.0nM, although it was found to be slightly weaker than THC in animal tests.[1]
References
- ^ Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry. 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID 15974991.
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- Pages using the JsonConfig extension
- Chem-molar-mass both hardcoded and calculated
- Infobox-drug molecular-weight unexpected-character
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- All stub articles